More than half of high-grade cervical lesions, which are abnormal tissue changes that can lead to cancer, are caused by persistent HPV infection that can be prevented if a person receives an HPV vaccine. Monitoring trends in the incidence of these lesions is helpful for evaluating the impact of HPV vaccination.
A team led by Susan Hariri, PhD, of the US Centers for Disease Control and Prevention, found that in the first few years after HPV vaccination was introduced in the United States (2008-2012), there were large and uniform declines in high-grade cervical lesions in young women across the country who were aged 18 to 20 years, and to a lesser extent, in women aged 21 to 24 years.
Dr. Hariri noted that high-grade cervical lesions are asymptomatic and can only be detected through routine cervical cancer screening. Because screening recommendations were changing during the time period of this study, the investigators also looked at trends in cervical cancer screening utilization. “In particular, screening is no longer recommended in women before age 21 years, and we found substantial declines in screening in 18 to 20 year olds that were consistent with the new recommendations,” said Dr. Hariri. While screening also declined in 21 to 24 year old women, the decreases in screening were much smaller. “We think that the decreases in high-grade lesions in this group reflect changes in screening but also may be partially due to HPV vaccination.” Dr. Hariri added that the greatest benefit of HPV vaccination—reducing the burden of cervical cancer and other HPV-associated cancers—will take many years to evaluate because of the long lag time between infection with HPV and the development of cancer.
In an accompanying editorial, Harinder Brar, MD and Allan Covens, MD, of the University of Toronto, stated that the study is significant because it is the first to look at the incidence trends of high-grade cervical lesions in the post-vaccination era. “The study highlights that while preliminary data demonstrates a drop in… incidence rates, the results may be confounded by the changes in cervical screening guidelines.”
Media wishing to receive a PDF of this article may contact firstname.lastname@example.org. (Would you prefer to access this paper instantly? You can register for a login to our Press Room here.)
Article: “Population-based trends in high-grade cervical lesions in the early HPV vaccine era, United States.” Susan Hariri, Michelle L. Johnson, Nancy M. Bennett, Heidi Bauer, Ina Park, Sean Schafer, Linda M. Niccolai, Elizabeth R. Unger, Lauri E. Markowitz, and the HPV-IMPACT Working Group. CANCER; Published Online: June 22, 2015 (DOI: 10.1002/cncr.29266).
Author Contact: Brian Katzowitz, of the CDC’s News Media Team, at (404) 639-1470, Mobile (404) 455-9924 or email@example.com.
Editorial: “Trends in CIN2+ post HPV Vaccination: The Devil is in the Details.” Harinder Brar and Allan Covens. CANCER; Published Online: June 22, 2015 (DOI: 10.1002/cncr.29264).
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology and course of human cancer. CANCER is published by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s website can be accessed at http://www.wiley.com.
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER News Room upon online publication. For more information or to obtain a PDF of any study, please contact:
Evelyn Martinez (US) +1 201 748 6358
Tom Griffin (UK) +44 (0) 1865 476213